Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
RIVAL-01 in MSS/pMMR/MSI-L Colorectal Carcinoma: NCT04301011 Clinical Landscape Report 2026
28 September 2026
NCT04301011 clinical landscape for MSS/pMMR/MSI-L Colorectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Taurine in Beta-Thalassemia: NCT04291352 Clinical Landscape Report 2026
28 September 2026
NCT04291352 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Omega-3-acid ethyl esters(Trygg Pharma AS) in Beta-Thalassemia: NCT04292314 Clinical Landscape Report 2026
28 September 2026
NCT04292314 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Mesothelioma, Malignant: NCT04300244 Clinical Landscape Report 2026
28 September 2026
NCT04300244 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
S-588210 in Lung Cancer: NCT04316689 Clinical Landscape Report 2026
28 September 2026
NCT04316689 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Unresectable Pleural Malignant Mesothelioma: NCT04400539 Clinical Landscape Report 2026
28 September 2026
NCT04400539 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Ledipasvir/Sofosbuvir in Beta-Thalassemia: NCT04353986 Clinical Landscape Report 2026
28 September 2026
NCT04353986 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Durvalumab in Malignant Pleural Mesothelioma: NCT04334759 Clinical Landscape Report 2026
28 September 2026
NCT04334759 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Mesothelioma: NCT04375267 Clinical Landscape Report 2026
28 September 2026
NCT04375267 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vamifeport hydrochloride in Beta-Thalassemia: NCT04364269 Clinical Landscape Report 2026
28 September 2026
NCT04364269 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talazoparib Tosylate in Malignant Mesothelioma of Peritoneum: NCT04462809 Clinical Landscape Report 2026
28 September 2026
NCT04462809 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Tovinontrine in Beta-Thalassemia: NCT04411082 Clinical Landscape Report 2026
28 September 2026
NCT04411082 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.